Last reviewed · How we verify
FLOT-CROSS or CROSS-FLOT
At a glance
| Generic name | FLOT-CROSS or CROSS-FLOT |
|---|---|
| Sponsor | Erasmus Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Induction FLOT With CROSS CRT for Esophageal Cancer (PHASE2)
- Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction (PHASE2)
- Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (PHASE3)
- NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLOT-CROSS or CROSS-FLOT CI brief — competitive landscape report
- FLOT-CROSS or CROSS-FLOT updates RSS · CI watch RSS
- Erasmus Medical Center portfolio CI